Viracta Therapeutics, Inc. (VIRX)
Largest Insider Buys in Sector
VIRX Stock Price History Chart
VIRX Stock Performance
About Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic …
Insider Activity of Viracta Therapeutics, Inc.
Over the last 12 months, insiders at Viracta Therapeutics, Inc. have bought $49,362 and sold $4,353 worth of Viracta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viracta Therapeutics, Inc. have bought $32,675 and sold $134,323 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothera Mark (President and CEO) — $98,723.
The last purchase of 47,906 shares for transaction amount of $23,627 was made by Rothera Mark (President and CEO) on 2023‑12‑01.
List of Insider Buy and Sell Transactions, Viracta Therapeutics, Inc.
| 2024-02-27 | Sale | CFO and COO | 3,405 0.0083% | $0.73 | $2,493 | -17.74% | ||
| 2023-12-01 | President and CEO | 47,906 0.1301% | $0.49 | $23,627 | +24.02% | |||
| 2023-11-30 | President and CEO | 52,094 0.1374% | $0.49 | $25,734 | +19.12% | |||
| 2023-11-28 | Sale | CFO and COO | 3,720 0.0096% | $0.50 | $1,860 | +14.96% | ||
| 2023-08-28 | Sale | CFO and COO | 3,512 0.0093% | $1.45 | $5,092 | -52.60% | ||
| 2023-05-25 | Sale | CFO and COO | 3,635 0.0091% | $1.42 | $5,160 | -43.34% | ||
| 2023-02-27 | Sale | CFO and COO | 3,599 0.0094% | $1.68 | $6,051 | -25.75% | ||
| 2023-02-27 | Sale | Chief Medical Officer | 2,156 0.0056% | $1.68 | $3,625 | -25.75% | ||
| 2022-11-28 | Sale | CFO and COO | 3,532 0.0101% | $2.72 | $9,606 | -42.66% | ||
| 2022-11-28 | Sale | Chief Medical Officer | 2,116 0.006% | $2.72 | $5,754 | -42.66% | ||
| 2022-08-25 | Sale | CEO & President | 13,379 0.0334% | $4.01 | $53,656 | -59.98% | ||
| 2022-08-25 | Sale | CFO and COO | 3,655 0.0091% | $4.02 | $14,679 | -59.98% | ||
| 2022-08-25 | Sale | Chief Medical Officer | 2,190 0.0055% | $4.01 | $8,786 | -59.98% | ||
| 2022-05-25 | Sale | CEO & President | 13,162 0.0338% | $1.90 | $25,022 | +14.72% | ||
| 2022-05-25 | Sale | CFO and COO | 3,596 0.0092% | $1.90 | $6,836 | +14.72% | ||
| 2022-05-25 | Sale | Chief Medical Officer | 2,154 0.0055% | $1.90 | $4,095 | +14.72% | ||
| 2022-02-28 | Sale | CEO & President | 14,635 0.0397% | $2.78 | $40,678 | +6.23% | ||
| 2022-02-28 | Sale | CFO and COO | 3,998 0.0108% | $2.78 | $11,112 | +6.23% | ||
| 2022-02-28 | Sale | Chief Medical Officer | 2,395 0.0065% | $2.78 | $6,657 | +6.23% | ||
| 2021-11-29 | Sale | CEO & President | 15,833 0.0446% | $4.82 | $76,301 | -22.10% |
Insider Historical Profitability
| Rothera Mark | President and CEO | 100000 0.2537% | $0.19 | 2 | 0 | |
| ALTA BIOPHARMA PARTNERS III LP | 10910596 27.6798% | $0.19 | 2 | 1 | +23.63% | |
| Aisling Capital IV, LP | 10 percent owner | 10100000 25.6233% | $0.19 | 1 | 0 | <0.0001% |
| BAY CITY CAPITAL LLC | 10 percent owner | 5267598 13.3637% | $0.19 | 2 | 6 | +23.63% |
| KERINS PATRICK J | 10 percent owner | 4659333 11.8206% | $0.19 | 2 | 5 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $3.69M | 9.2 | 3.61M | 0% | +$0 | 0.03 | |
| Citadel Advisors LLC | $1.6M | 3.99 | 1.57M | +2.36% | +$36,852.60 | <0.01 | |
| The Vanguard Group | $1.18M | 2.96 | 1.16M | 0% | +$0 | <0.0001 | |
| Samsara Biocapital Llc | $703,503.00 | 1.76 | 689,709 | 0% | +$0 | 0.11 | |
| Laurion Capital Management LP | $428,835.00 | 1.07 | 420,426 | -25.32% | -$145,420.54 | <0.01 |